Mandate

Vinge’s Forensic, Risk & Compliance Group assists Tele2

Tele2 has decided to leave Kazakhstan and has today published the terms and conditions governing the transaction.

In connection with the exit, Tele2 has issued the extensive report "Tele2 Kazakhstan - Exit Report on Ethics and Compliance". The Exit Report is part of Tele2’s obligation to act ethically, to fight corruption and be transparent to shareholders and the market. 
 
Vinge’s Forensic, Risk & Compliance Group has assisted Tele2 in conjunction with the company’s analysis and reporting of the anti‑corruption work which Tele2 has conducted since it arrived in Kazakhstan. In the Exit Report, Tele2 describes its method of identifying and addressing corruption risks. This method is based on Vinge’s formulated best practice – a compliance programme consisting of 10 steps which companies and organizations should implement in order to prevent bribery and corruption in their business operations. 

“It is very satisfying to work with a company which takes the risks of corruption seriously. It is not possible to prevent everything, although you can establish a framework and procedures which minimize the risk significantly”,

says Mia Falk, Head of Forensic, Risk & Compliance at Vinge.

For more information, please see Tele2’s press release as well as Tele2 Kazakhstan - Exit Report on Ethics and Compliance

Vinge’s team consisted of Mia Falk and Hayaat Ibrahim.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025